CN1571796A - 黑皮素受体配体 - Google Patents

黑皮素受体配体 Download PDF

Info

Publication number
CN1571796A
CN1571796A CNA01816384XA CN01816384A CN1571796A CN 1571796 A CN1571796 A CN 1571796A CN A01816384X A CNA01816384X A CN A01816384XA CN 01816384 A CN01816384 A CN 01816384A CN 1571796 A CN1571796 A CN 1571796A
Authority
CN
China
Prior art keywords
hydrogen
alkyl
group
milliliters
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA01816384XA
Other languages
English (en)
Chinese (zh)
Inventor
F·H·埃伯蒂诺
A·W·马苏
J·C·海斯
王峰
M·G·索林斯基
A·－O·科尔森
林启圣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Ltd
Procter and Gamble Co
Original Assignee
Procter and Gamble Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Ltd filed Critical Procter and Gamble Ltd
Publication of CN1571796A publication Critical patent/CN1571796A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
CNA01816384XA 2000-09-27 2001-09-26 黑皮素受体配体 Pending CN1571796A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23585800P 2000-09-27 2000-09-27
US60/235,858 2000-09-27

Publications (1)

Publication Number Publication Date
CN1571796A true CN1571796A (zh) 2005-01-26

Family

ID=22887187

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA01816384XA Pending CN1571796A (zh) 2000-09-27 2001-09-26 黑皮素受体配体

Country Status (19)

Country Link
EP (1) EP1409540A2 (fr)
JP (1) JP2004509974A (fr)
KR (1) KR100519204B1 (fr)
CN (1) CN1571796A (fr)
AR (1) AR030806A1 (fr)
AU (2) AU2001296313B2 (fr)
BR (1) BR0114257A (fr)
CA (1) CA2420045A1 (fr)
CZ (1) CZ2003788A3 (fr)
HU (1) HUP0303085A2 (fr)
IL (1) IL154437A0 (fr)
MX (1) MXPA03002691A (fr)
NO (1) NO20031287D0 (fr)
NZ (1) NZ524190A (fr)
PE (1) PE20020447A1 (fr)
PL (1) PL362003A1 (fr)
RU (1) RU2246501C2 (fr)
WO (1) WO2002026774A2 (fr)
ZA (1) ZA200301561B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106966927A (zh) * 2017-04-13 2017-07-21 菲立化学工程（上海）有限公司 一种抗艾滋病药物中间体重氮酮与氯酮的合成方法

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
ATE550041T1 (de) 2004-01-21 2012-04-15 Novo Nordisk Healthcare Ag Transglutaminase-vermittelte konjugation von peptiden
RU2309144C2 (ru) * 2005-03-25 2007-10-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фенилсодержащие n-ацильные производные аминов, способ их получения, фармацевтическая композиция и их применение в качестве противовоспалительных и анальгетических средств
US8247530B2 (en) 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
NZ571300A (en) 2006-04-07 2011-12-22 Warner Chilcott Co Llc Antibodies that bind human protein tyrosine phosphatase beta (HPTPBeta) and uses thereof
RU2303597C1 (ru) * 2006-05-12 2007-07-27 Иващенко Андрей Александрович Фармацевтическая композиция, способы ее получения и применения
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
WO2008107362A2 (fr) * 2007-03-07 2008-09-12 Novo Nordisk Health Care Ag Nouveaux inhibiteurs du facteur de coagulation sanguine
EA018630B1 (ru) 2008-06-09 2013-09-30 Палатин Текнолоджиз, Инк. Специфичные к меланокортиновым рецепторам пептиды для лечения сексуальной дисфункции
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2010144341A2 (fr) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Peptides spécifiques des récepteurs aux mélanocortines à pont lactame
EA020959B1 (ru) 2009-06-08 2015-03-31 Палатин Текнолоджиз, Инк. Пептиды, специфичные к меланокортиновым рецепторам
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
DK2451279T3 (da) 2009-07-06 2019-05-20 Aerpio Therapeutics Inc Benzosulfonamid derivater forbindelser deraf og deres brug til at forhindre metastaser af cancerceller
RU2012125033A (ru) * 2009-11-16 2014-01-20 Ипсен Фарма С.А.С. СПОСОБ СИНТЕЗА Ас-Arg-ЦИКЛО(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
JP2013511554A (ja) 2009-11-23 2013-04-04 パラティン テクノロジーズ，インコーポレイテッド メラノコルチン−１受容体特異的線状ペプチド
BR112012011787B1 (pt) 2009-11-23 2022-03-03 Palatin Technologies, Inc Peptídeo cíclico e composição farmacêutica
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
KR102331588B1 (ko) 2014-05-12 2021-11-30 캐패시터 사이언시스 인코포레이티드 에너지 저장 디바이스 및 이의 생산 방법
US10347423B2 (en) 2014-05-12 2019-07-09 Capacitor Sciences Incorporated Solid multilayer structure as semiproduct for meta-capacitor
US10340082B2 (en) 2015-05-12 2019-07-02 Capacitor Sciences Incorporated Capacitor and method of production thereof
WO2016073522A1 (fr) 2014-11-04 2016-05-12 Capacitor Sciences Incorporated Dispositifs de stockage d'énergie et leurs procédés de fabrication
RU2017128756A (ru) 2015-02-26 2019-03-27 Кэпэситор Сайенсиз Инкорпорейтед Самовосстанавливающийся конденсатор и способы его получения
US9932358B2 (en) * 2015-05-21 2018-04-03 Capacitor Science Incorporated Energy storage molecular material, crystal dielectric layer and capacitor
US9941051B2 (en) 2015-06-26 2018-04-10 Capactor Sciences Incorporated Coiled capacitor
US10026553B2 (en) 2015-10-21 2018-07-17 Capacitor Sciences Incorporated Organic compound, crystal dielectric layer and capacitor
US10305295B2 (en) 2016-02-12 2019-05-28 Capacitor Sciences Incorporated Energy storage cell, capacitive energy storage module, and capacitive energy storage system
US9978517B2 (en) 2016-04-04 2018-05-22 Capacitor Sciences Incorporated Electro-polarizable compound and capacitor
US10153087B2 (en) 2016-04-04 2018-12-11 Capacitor Sciences Incorporated Electro-polarizable compound and capacitor
US10395841B2 (en) 2016-12-02 2019-08-27 Capacitor Sciences Incorporated Multilayered electrode and film energy storage device

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350430B1 (en) * 1997-10-27 2002-02-26 Lion Bioscience Science Ag Melanocortin receptor ligands and methods of using same
ID30262A (id) * 1999-03-29 2001-11-15 Procter & Gamble Ligan reseptor melanokortin
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106966927A (zh) * 2017-04-13 2017-07-21 菲立化学工程（上海）有限公司 一种抗艾滋病药物中间体重氮酮与氯酮的合成方法

Also Published As

Publication number Publication date
MXPA03002691A (es) 2003-06-06
CA2420045A1 (fr) 2002-04-04
PL362003A1 (en) 2004-10-18
WO2002026774A2 (fr) 2002-04-04
NZ524190A (en) 2004-09-24
CZ2003788A3 (cs) 2003-08-13
BR0114257A (pt) 2003-07-01
JP2004509974A (ja) 2004-04-02
EP1409540A2 (fr) 2004-04-21
IL154437A0 (en) 2003-09-17
NO20031287L (no) 2003-03-20
KR100519204B1 (ko) 2005-10-06
AU2001296313B2 (en) 2005-06-02
PE20020447A1 (es) 2002-07-02
NO20031287D0 (no) 2003-03-20
RU2246501C2 (ru) 2005-02-20
AR030806A1 (es) 2003-09-03
KR20030061814A (ko) 2003-07-22
HUP0303085A2 (hu) 2003-12-29
AU9631301A (en) 2002-04-08
WO2002026774A3 (fr) 2003-03-27
ZA200301561B (en) 2004-03-10

Similar Documents

Publication Publication Date Title
CN1571796A (zh) 黑皮素受体配体
CN1249086C (zh) 黑素皮质素受体配体
CN1052731C (zh) 具有生长激素释放特性的化合物
CN1183158C (zh) Exendin类似物,其制备方法及含有它们的药物制剂
CN1149210C (zh) 凝血酶抑制剂
CN1192035C (zh) 白介素－1β转化酶抑制剂
CN1543461A (zh) 黑皮素受体配体
CN1272114A (zh) 苯乙胺衍生物
CN1451017A (zh) 选择性环肽
CN1311796A (zh) 肽类抗血管生成药
CN1918131A (zh) 新的谷氨酰胺酰基环化酶抑制剂
CN1674927A (zh) 生长激素释放肽
CN1622822A (zh) 含有生长素释放肽的药物组合物
CN101077875A (zh) 硼酸酯和硼酸化合物,其合成和应用
CN1114961A (zh) 细胞粘连肽抑制剂
CN1946691A (zh) 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的化合物
CN1261281A (zh) 肽甲状旁腺激素类似物
CN101076516A (zh) 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的硫化合物
CN1041950A (zh) 新型肽酶抑制剂
CN1150206C (zh) 含有n-取代甘氨酸的血管舒缓激肽拮抗剂肽
CN1436175A (zh) 作为Aβ－蛋白生产抑制剂的环状内酰胺
CN1329620A (zh) 胰高血糖素样肽－1的类似物
CN1237978A (zh) N－(芳基/杂芳基)氨基酸衍生物、包括这些衍生物的药用组合物以及用这些化合物抑制β－淀粉样肽释放和或其合成的方法
CN1351609A (zh) 低分子量补体蛋白酶抑制剂
CN1195776C (zh) 肥胖症的治疗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication